InflaRx (IFRX) Stock: Buy, Sell, or Hold?
IFRX - InflaRx N.V. Common Stock
$2.09
0.04 (1.95%)
â˛
5d:
-6.28%
30d:
+3.98%
90d:
+24.4%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When IFRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IFRX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IFRX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: IFRX is currently trading at $2.09, which is considered fair relative to its 30-day fair value range of $1.93 to $2.27.
Technical Outlook: Technically, IFRX is showing sideways momentum. Immediate support is located at $1.98, while resistance sits at $2.38.
Market Sentiment: IFRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.92 (+279.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IFRX is showing sideways momentum. Immediate support is located at $1.98, while resistance sits at $2.38.
Market Sentiment: IFRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.92 (+279.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.93 -
$2.27
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 279.2% below Wall St target ($7.92)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.93 -
$2.27
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.38
(18.0%)
Support & Resistance Levels
Support Level
$1.98
Resistance Level
$2.38
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.04
Wall Street Target
$7.93
(+279.2%)
Revenue Growth (YoY)
-80.8%
Share & Embed Analysis
Last updated: September 13, 2026 11:57 AM ET
Data refreshes hourly during market hours. Next update: 12:57 PM
Data refreshes hourly during market hours. Next update: 12:57 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IFRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
